Grant name: Assay Validation of High Quality Markers for Clinical Studies in Cancer
Funding organization: National Institutes of Health (NIH), National Cancer Institute (NCI)
Total funding amount: Up to $275,000 for UH2 phase; Up to $250,000 per year for UH3 phase
Duration: UH2 phase up to 2 years; UH3 phase up to 3 years
Primary objective: Support validation of biomarkers and assays for cancer-related studies
Funding source: Federal government
Funding type: Cooperative agreement
Significance: Addresses critical needs in cancer research and clinical trials
Grant frequency: One-time funding opportunity
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
Federal Governments
Eligible Agencies of the Federal Government
U.S. Territory or Possession
Other: Independent School Districts, Public Housing Authorities, Faith-based Organizations
Non-domestic (non-U.S.) Entities are not eligible to apply.
Non-domestic components of U.S. Organizations are not eligible.
Validation of molecular/cellular/imaging markers for cancer detection, diagnosis, prognosis, and treatment response.
Support for investigator-initiated research for analytical and clinical validation of assays.
Applicants must have assays that work on human samples.
Assays must be justified for development into clinical assays.
Applicants may request up to $275,000 direct costs for the UH2 phase.
No more than $200,000 can be requested in any one year for UH2.
Up to $250,000 direct costs for the UH3 phase per year.
Open Date: January 14, 2025
Application Due Dates: Various dates from June 11, 2025 to October 14, 2026
Expiration Date: October 15, 2026
Compliance with NIH Grants Policy Statement is required.
Assays must be performed in CLIA-certified laboratories if intended for medical decision-making.
Applications must be submitted electronically through Grants.gov.
Adherence to the application instructions in the Research Instructions is critical.